Drug Type Bispecific antibody |
Synonyms RNDO-Program 3 (Rondo) |
Target |
Action inhibitors, stimulants |
Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Endometrial Carcinoma | Discovery | United States | 01 Jun 2025 |






